Merck Sharp & Dohme 10K 2004 Annual report | SEC Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: aboutVioxx, abuse, ACR, additionalVioxx, additionalVioxxProduct, adequacy, adjudication, aid, Alabama, allVioxxProduct, allVioxxShareholder, andHaemophilusinfluenza, andRotaTeqin, andVarivax, andVioxxShareholder, answer, Antonio, appellate, apply, arbitration, argued, arise, asInegyin, attestation, Aurora, Australian, awaiting, aware, bioavailable, BMS, brandedEzetroloutside, Brazil, burdensome, cancel, certainVioxxProduct, cervical, Chesler, CHMP, College, colorectal, Columbia, concerningVioxx, conclusion, congestive, Congressional, contest, contractor, COSO, decreased, deliver, detecting, disabled, discharged, disposition, DOV, dual, duration, Eldon, EMEA, empirical, enalaprilat, endocrine, enrichment, evaluateVytorinin, event, excreted, extend, extent, fall, Fallon, febrile, filable, Finance, forArcoxiaare, forArcoxiaspecifically, forCancidaswere, forGardasil, forGardasilin, forHyzaarfor, forVioxx, forVioxxfrom, forZetiaandVytorin, framework, Frameworkissued, fraudulent, FRC, full, genital, glaucoma, GlaxoSmithKline, Graph, Grassley, GSK, Guaranty, healthy, heard, hereinafter, history, hormone, Hunterdon, impeding, implicated, improper, inactive, includeVioxx, includingArcoxia, includingHaemophilusinfluenzae, includingZetiaandVytorin, incomplete, Indenture, indeterminate, inInternal, Inspector, integrated, irrespective, ischemic, Israel, JPML, Kentucky, kinase, leave, lifted, lipid, lipoprotein, lowest, LSC, Maryland, MDL, measure, media, mentioned, metabolized, Minnesota, mismanagement, month, Morgan, Multidistrict, multiple, Munich, muraglitazar, Nasal, Nassau, Nastech, nationwide, needy, neutropenic, NJ, nominal, nonsteroidal, obligation, ofArcoxia, ofFosamaxto, ofPropeciaand, ofVioxx, ofVioxxand, ofVioxxin, ofVioxxpurchased, older, ono, Onondaga, onset, onVioxx, onVytorin, Opposition, overcharged, paragraph, payor, Peptide, permission, petitioner, placebo, play, pneumococcal, Polyp, polyvalent, PPAR, precautionary, prejudice, proceed, prolonged, proof, PYY, Quantitative, randomized, reconsideration, reconsidered, recovered, recovering, recurrence, refund, regardingVioxxin, reinstated, reinvestment, revised, revoke, revoking, Rheumatology, ROCHELLE, SAHA, San, Sanofi, SEC, Senate, Senator, sevenVioxxDerivative, shortest, show, similarly, Southern, spent, Sponsoring, Spray, Standardsapplicable, Stanley, statutorily, stopped, substantive, sugar, suggested, summary, Superior, Supplementary, Swedish, takenVioxxin, takingVioxxcompared, territory, thatArcoxiamay, theVioxx, theVioxxDerivative, theVioxxERISA, theVioxxLitigation, theVioxxProduct, theVioxxShareholder, thought, thrombotic, toArcoxia, toVioxxin, toVioxxwill, toxicology, transverse, Treadway, triglyceride, Trustee, tumor, unable, undergo, underlying, undetermined, unduly, unjust, unsuccessful, unusedVioxxwill, urogenital, VasereticandVasotec, version, Vertex, view, VioxxDerivative, VioxxERISA, VioxxLitigation, VioxxProduct, VioxxShareholder, void, warranted, Wisconsin, withdrawn, withdrewVioxxfrom, writing, YY

Removed: accompanied, Andersen, Arthur, body, check, debt, elevated, exclusively, family, furnish, Hoechst, influenzae, losartan, mailing, Maxalt, Northern, payer, processing, Propecia, represent, rheumatoid, sued


Dated: March 11, 2005		/s/ Judy C. Lewent

	Name:	Judy C. Lewent
	Title:	Executive Vice President & Chief Financial Officer President, Human Health Asia

Merck Sharp & Dohme 10-K2004 FY Annual report

Content analysis